Pfizer: Pharma Dividend Superstar

  • Pfizer received FDA approvals for key cancer drugs in the US and Europe.
  • The company reported a 2 percent decline in its quarterly revenue numbers.
  • Pfizer looks to stem the decline by introducing up to 30 new products in the next five years.

By S. Mitra, MBA

Pfizer Inc. (NYSE:PFE) stock comes with a rather formidable dividend yield of 3.92 percent, which, coupled with a strong growth rate, makes it one of the dividend superstars in the pharma sector. The stock currently trades almost midway between its 52 weeks low and high of $29.83 and $35.38 respectively and thus offers a good point to build a position. The company recently reported rather tepid quarterly numbers but made up for those with a few product approvals. Management's decision to raise EPS guidance is also a sign of good things to come.

The full post is available to investor members only. Subscribe here.